BridgeBio Pharma, Inc. (BBIO)
Largest Insider Buys in Sector
BBIO Stock Price History Chart
BBIO Stock Performance
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 …
Insider Activity of BridgeBio Pharma, Inc.
Over the last 12 months, insiders at BridgeBio Pharma, Inc. have bought $0 and sold $155.42M worth of BridgeBio Pharma, Inc. stock.
On average, over the past 5 years, insiders at BridgeBio Pharma, Inc. have bought $2M and sold $139.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $100,680 was made by Ellis Andrea () on 2022‑03‑15.
List of Insider Buy and Sell Transactions, BridgeBio Pharma, Inc.
| 2024-11-19 | Sale | Chief Executive Officer | 27,389 0.0145% | $22.41 | $613,826 | 0.00% | ||
| 2024-11-19 | Sale | Secretary, Treasurer & CFO | 4,156 0.0022% | $22.41 | $93,137 | 0.00% | ||
| 2024-09-13 | Sale | 10 percent owner | 5.8M 3.0339% | $25.75 | $149.35M | -1.07% | ||
| 2024-08-19 | Sale | Chief Executive Officer | 27,389 0.0143% | $24.69 | $676,256 | +3.02% | ||
| 2024-08-19 | Sale | Secretary, Treasurer & CFO | 4,155 0.0022% | $24.69 | $102,590 | +3.02% | ||
| 2024-06-04 | Sale | director | 1,500 0.0009% | $31.30 | $46,950 | -3.57% | ||
| 2024-06-03 | Sale | director | 1,000 0.0005% | $28.84 | $28,843 | -9.66% | ||
| 2024-03-01 | Sale | director | 2,500 0.0014% | $34.00 | $85,000 | -24.17% | ||
| 2024-02-15 | Sale | director | 2,915 0.0018% | $37.75 | $110,041 | -30.87% | ||
| 2024-01-16 | Sale | director | 2,915 0.0017% | $37.97 | $110,683 | -26.14% | ||
| 2023-12-26 | Sale | director | 100,000 0.0575% | $42.06 | $4.21M | -34.24% | ||
| 2023-12-18 | Sale | director | 2,000 0.0012% | $40.00 | $80,000 | -27.58% | ||
| 2023-12-15 | Sale | director | 2,915 0.0015% | $36.12 | $105,290 | -28.67% | ||
| 2023-12-01 | Sale | director | 2,500 0.0014% | $29.40 | $73,500 | -8.44% | ||
| 2023-11-17 | Sale | CEO and President | 51,552 0.0296% | $29.10 | $1.5M | -2.59% | ||
| 2023-11-17 | Sale | Secretary, Treasurer & CFO | 22,685 0.013% | $29.10 | $660,059 | -2.59% | ||
| 2023-11-15 | Sale | director | 2,915 0.0017% | $30.00 | $87,450 | -4.34% | ||
| 2023-09-05 | Sale | director | 2,500 0.0016% | $30.00 | $75,000 | -3.76% | ||
| 2023-08-17 | Sale | CEO and President | 51,552 0.0322% | $28.59 | $1.47M | +0.92% | ||
| 2023-08-17 | Sale | Secretary, Treasurer & CFO | 22,683 0.0142% | $28.59 | $648,455 | +0.92% |
Insider Historical Profitability
| KKR Genetic Disorder L.P. | 10 percent owner | 25260971 13.3663% | $26.49 | 1 | 3 | +7.23% |
| STEPHENSON BRIAN C | Secretary, Treasurer & CFO | 93758 0.0496% | $26.49 | 2 | 27 | +7.23% |
| Scott Randal W. | director | 4000 0.0021% | $26.49 | 1 | 6 | |
| Valantine Hannah | director | 1764 0.0009% | $26.49 | 2 | 4 | <0.0001% |
| VIKING GLOBAL PERFORMANCE LLC | 10 percent owner | 26620991 14.0859% | $26.49 | 1 | 0 | +6.17% |